Aspira Women's Health Appoints New CMO, Director
Ticker: AWHL · Form: 8-K · Filed: Jul 29, 2024 · CIK: 926617
| Field | Detail |
|---|---|
| Company | Aspira Women'S Health INC. (AWHL) |
| Form Type | 8-K |
| Filed Date | Jul 29, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, personnel
TL;DR
Aspira Women's Health brings in a new CMO and a new board member, signaling potential changes.
AI Summary
Aspira Women's Health Inc. announced on July 25, 2024, the appointment of Dr. Michael J. Nally as Chief Medical Officer and the election of Ms. Karen L. King to its Board of Directors. The company also disclosed compensatory arrangements for certain officers, though specific dollar amounts for these arrangements were not detailed in this filing.
Why It Matters
The appointment of a new Chief Medical Officer and a new Board member can signal strategic shifts or a renewed focus on medical innovation and governance for Aspira Women's Health.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can indicate internal shifts that may impact the company's future strategy and performance.
Key Players & Entities
- Aspira Women's Health Inc. (company) — Registrant
- Dr. Michael J. Nally (person) — Appointed Chief Medical Officer
- Ms. Karen L. King (person) — Elected to Board of Directors
- July 25, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Aspira Women's Health Inc.?
Dr. Michael J. Nally has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors of Aspira Women's Health Inc.?
Ms. Karen L. King has been elected to the Board of Directors.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is July 25, 2024.
What specific compensatory arrangements were disclosed for certain officers?
The filing mentions compensatory arrangements for certain officers but does not detail specific dollar amounts in the provided text.
What is the Standard Industrial Classification code for Aspira Women's Health Inc.?
The Standard Industrial Classification code for Aspira Women's Health Inc. is 2835, which corresponds to IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
Filing Stats: 628 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2024-07-29 16:04:59
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AWH Nasdaq Capital Market
Filing Documents
- awh-20240725.htm (8-K) — 57KB
- awh-ex99_1.htm (EX-99.1) — 16KB
- img245972787_0.jpg (GRAPHIC) — 912KB
- 0000950170-24-087276.txt ( ) — 1441KB
- awh-20240725.xsd (EX-101.SCH) — 31KB
- awh-20240725_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Aspira Women's Health on July 29, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASPIRA WOMEN'S HEALTH INC. Date: July 29, 2024 By: /s/ Nicole Sandford Nicole Sandford Chief Executive Officer